IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. It offers micro-miniature products, microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components, and assemblies and software solutions for medical devices, hearing healthcare, and professional audio communication devices markets. The company also provides micro coils for surgical navigation clinical applications, such as interventional pulmonology, and electrophysiology; joint engineering and manufacturing services for complex medical devices, including catheters covering a range of applications for cardiology, peripheral vascular, neurology, radiology, and pulmonology; bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system; and safety needle products for original equipment manufacturing customers. In addition, it offers professional audio headset products used for emergency response needs in the fire, law enforcement, safety, aviation, and military markets; and a line of miniature ear-and head-worn devices used by performers and support staff in the music and stage performance markets. The company sells its hearing device products, and medical and professional audio communications products directly to hearing instrument manufacturers, distributors, and partnerships; and microphone products to the radio communication and professional audio industries, as well as markets and sells hearing aid devices directly to consumers through direct mail advertising, Internet, and call center. The company was formerly known as Selas Corporation of America and changed its name to IntriCon Corporation. The company was incorporated in 1930 and is headquartered in Arden Hills, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: intricon.com
ARDEN HILLS, Minn., May 24, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced the completion of its acquisition by funds affiliated with Altaris Capital Partners, LLC (together with certain affiliated entities, "Altaris") for $24.25 per share in cash, or approximately $241 million on a fully diluted basis. The transaction was announced on February 28, 2022, and received approval from stockholders on May 24, 2022. As a result of the transaction, Intricon is now a privately he
ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di
ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced that it has entered into a definitive agreement whereby an affiliate of Altaris Capital Partners, LLC (collectively with its affiliates, "Altaris"), an investment firm focused exclusively on the healthcare industry, will acquire the company. Under the terms of the agreement, Altaris will acquire all outstanding shares of Intricon for $24.25 per share in a transaction that values Intricon at an equ
ARDEN HILLS, Minn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced that Scott Longval, Intricon's President and Chief Executive Officer, will present at the upcoming Virtual 2021 Stifel Healthcare Conference. Intricon is scheduled to present on Monday, November 15, 2021 at 10:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company's website at: www.intricon.com. About Intricon
ARDEN HILLS, Minn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its third quarter ended September 30, 2021. Third Quarter 2021 Highlights: Revenue of $31.1 million, a 13.5% increase compared to the prior year periodGross profit margin of 23.1%, compared to 26.3% in the prior year periodGAAP net income of $337,000 versus net income of $644,000 in the prior year periodNon-GAAP adjusted net income of $1.7 million versus $2.4 m
ARDEN HILLS, Minn., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, announced today that Ellen Scipta has stepped down from her position as Chief Financial Officer, effective October 29, 2021. Annalee Lutgen, current Treasurer and Director of Finance, will serve as interim Chief Financial Officer effective upon Ms. Scipta's resignation as the company conducts its search for a permanent replacement. "We appreciate the contributions Ellen has made to Intricon during her tenure h
ARDEN HILLS, Minn., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international company engaged in designing, developing, engineering and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that it will release its 2021 third quarter results on Monday, November 8, 2021, after market close. Following the release, Intricon's management team will host a conference call on the same day, beginning at 4:00 p.m. CT/5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (866) 795-7248 for domestic callers or (470) 495-9160 for international callers, using conference ID: 1489078. A live an
OTC Hearing Aid Act designed to offer greater public access to hearing aids at a lower costIntricon well positioned to provide the ecosystem necessary to deliver high customer satisfaction ARDEN HILLS, Minn., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), a joint development manufacturer of micromedical technology for use in interventional, implantable, and body-worn medical devices, strongly supports the U.S. Food and Drug Administration (FDA) proposal to improve access to and reduce the cost of hearing aid technology for millions of Americans. On October 19, 2021, the FDA proposed a rule to establish a new regulatory category of over-the-counter (OTC) hearing aids
ARDEN HILLS, Minn., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), a joint development manufacturer of micromedical technology for use in interventional, implantable, and body-worn medical devices, announced that it has achieved a critical milestone in the clinical study of its proprietary software that will allow people to self-fit hearing aids that are sold over-the-counter at retail stores and online. Summative Usability Validation has been completed, which demonstrates that users can safely and correctly use the Intricon self-fitting technology, and the clinical trial of the software can move forward. The milestone is meaningful in the progression of the study,
ARDEN HILLS, Minn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its second quarter ended June 30, 2021. Second Quarter Highlights: Revenue of $30.2 million, a 28% increase compared to the prior year periodGross profit margin of 26.1%, compared to 28.0% in the prior year periodGAAP net loss of $1.2 million versus net loss of $2.3 million in the prior year periodNon-GAAP adjusted net income of $2.1 million versus $2.1 million in the prio
4 - INTRICON CORP (0000088790) (Issuer)
4 - INTRICON CORP (0000088790) (Issuer)
4 - INTRICON CORP (0000088790) (Issuer)
4 - INTRICON CORP (0000088790) (Issuer)
4 - INTRICON CORP (0000088790) (Issuer)
4 - INTRICON CORP (0000088790) (Issuer)
4 - INTRICON CORP (0000088790) (Issuer)
4 - INTRICON CORP (0000088790) (Issuer)
4 - INTRICON CORP (0000088790) (Issuer)
4 - INTRICON CORP (0000088790) (Issuer)
ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di
ARDEN HILLS, Minn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its third quarter ended September 30, 2021. Third Quarter 2021 Highlights: Revenue of $31.1 million, a 13.5% increase compared to the prior year periodGross profit margin of 23.1%, compared to 26.3% in the prior year periodGAAP net income of $337,000 versus net income of $644,000 in the prior year periodNon-GAAP adjusted net income of $1.7 million versus $2.4 m
ARDEN HILLS, Minn., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, announced today that Ellen Scipta has stepped down from her position as Chief Financial Officer, effective October 29, 2021. Annalee Lutgen, current Treasurer and Director of Finance, will serve as interim Chief Financial Officer effective upon Ms. Scipta's resignation as the company conducts its search for a permanent replacement. "We appreciate the contributions Ellen has made to Intricon during her tenure h
ARDEN HILLS, Minn., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international company engaged in designing, developing, engineering and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that it will release its 2021 third quarter results on Monday, November 8, 2021, after market close. Following the release, Intricon's management team will host a conference call on the same day, beginning at 4:00 p.m. CT/5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (866) 795-7248 for domestic callers or (470) 495-9160 for international callers, using conference ID: 1489078. A live an
ARDEN HILLS, Minn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its second quarter ended June 30, 2021. Second Quarter Highlights: Revenue of $30.2 million, a 28% increase compared to the prior year periodGross profit margin of 26.1%, compared to 28.0% in the prior year periodGAAP net loss of $1.2 million versus net loss of $2.3 million in the prior year periodNon-GAAP adjusted net income of $2.1 million versus $2.1 million in the prio
ARDEN HILLS, Minn., July 26, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international company engaged in designing, developing, engineering and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that it will release its 2021 second quarter results on Monday, August 9, 2021, after market close. Following the release, Intricon's management team will host a conference call on the same day, beginning at 4:00 p.m. CT/5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (866) 795-7248 for domestic callers or (470) 495-9160 for international callers, using conference ID: 6328219. A live and
B. Riley resumed coverage of IntriCon with a rating of Buy and set a new price target of $32.00 from $28.00 previously
15-12B - INTRICON CORP (0000088790) (Filer)
8-K - INTRICON CORP (0000088790) (Filer)
S-8 POS - INTRICON CORP (0000088790) (Filer)
S-8 POS - INTRICON CORP (0000088790) (Filer)
S-8 POS - INTRICON CORP (0000088790) (Filer)
S-8 POS - INTRICON CORP (0000088790) (Filer)
S-8 POS - INTRICON CORP (0000088790) (Filer)
S-8 POS - INTRICON CORP (0000088790) (Filer)
S-8 POS - INTRICON CORP (0000088790) (Filer)
S-8 POS - INTRICON CORP (0000088790) (Filer)
ARDEN HILLS, Minn., March 22, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced the appointment of Kathleen Pepski to the company’s Board of Directors, effective March 19, 2021. “We are delighted to welcome Kathleen to Intricon and our board of directors,” said Scott Longval, President and Chief Executive Officer of Intricon. “Kathleen is a well-respected business leader in Minneapolis whose background in manufacturing and distribution, as well as mergers and acquisitions, will be instrumental in our long
ARDEN HILLS, Minn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that Ellen Scipta has been appointed Chief Financial Officer (CFO), effective immediately. As a key member of Intricon's executive leadership team, Ms. Scipta will lead the company’s financial operations and aid the management team on growing Intricon. “We are extremely pleased to welcome a strong leader like Ellen to the Intricon team. Her unique skill set that blends engineering with extensive financial experience will be inva
SC 13D/A - INTRICON CORP (0000088790) (Subject)
SC 13D/A - INTRICON CORP (0000088790) (Subject)
SC 13D/A - INTRICON CORP (0000088790) (Subject)
SC 13D/A - INTRICON CORP (0000088790) (Subject)
SC 13G/A - INTRICON CORP (0000088790) (Subject)
SC 13G - INTRICON CORP (0000088790) (Subject)
SC 13D/A - INTRICON CORP (0000088790) (Subject)
SC 13G/A - INTRICON CORP (0000088790) (Subject)
SC 13D/A - INTRICON CORP (0000088790) (Subject)
SC 13G/A - INTRICON CORP (0000088790) (Subject)
On Tuesday, shares of IntriCon Corporation (NASDAQ:IIN) experienced volatile short activity. After the activity, the stock price went up 0.4% to $24.24 The overall sentiment for IIN has been Bullish. The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Increase Short Exposure. The volatility alert was produced on the prior trading date, 5/24/2022, with a volatility change of +47.45%. The current volatility indicator stands at 8.519. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers. When u
Merger activity increased last week with six new deals announced and six deals completed. Three of the six new deals announced were potential deals in the works. Healthcare Trust of America (NYSE:HTA) Founded in 2006, Healthcare Trust of America is a healthcare focused REIT and the largest operator of dedicated medical office buildings (MOB) in the United States. The company owns real estate though 461 on-campus and off-campus properties around hospitals and Universities in 32 states. We added HTA to our ‘Deals in the Works‘ tool on October 6, 2021, when Bloomberg reported that activist investor Elliott Investment Management was pushing for the company to launch a strategic review that inc
U.S. stocks traded lower in another volatile session toward the end of trading on Monday, amid the ongoing Russia-Ukraine conflict, which has led to increased U.S. sanctions on Russia. The Dow traded down 1.53% to 33,536.93 while the NASDAQ fell 0.93% to 13,567.48. The S&P also fell, dropping, 1.39% to 4,323.90. Check out this: Insiders Buy Around $98M Of 3 Stocks Leading and Lagging Sectors Energy shares climbed by 1.6% on Friday. Meanwhile, top gainers in the sector included Renewable Energy Group, Inc. (NASDAQ:REGI), up 40% and Nordic American Tankers Limited (NYSE:NAT) up 23%. In trading on Friday, consumer staples shares fell by 2.1%. Top Headline Dentsply Sirona Inc (NAS
Gainers IntriCon (NASDAQ:IIN) shares increased by 37.4% to $23.93 during Monday's regular session. The current volume of 1.0 million shares is 3684.0% of IntriCon's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $218.7 million. The company's, Q4 earnings came out today. Reata Pharmaceuticals (NASDAQ:RETA) stock moved upwards by 22.46% to $32.0. The current volume of 1.7 million shares is 185.7% of Reata Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $1.1 billion. As per the press release, Q4 earnings came out today. Cormedix
Altaris Capital Partners LLC will acquire Implantable device maker Intricon Corporation (NASDAQ:IIN) for $24.25 per share in a transaction that values Intricon at an equity value of approximately $241 million. The purchase price represents a premium of approximately 39% to Intricon's closing stock price on February 25. Intricon expects to hold a Special Meeting of Shareholders to consider and vote on the proposed merger and the merger agreement. "We are excited to enter into this transaction with Altaris, which will deliver a compelling valuation to our shareholders and enable us to accelerate the advancement of our joint development manufacturing capabilities in micro medical technolo
Gainers Mullen Automotive, Inc. (NASDAQ:MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group, Inc. (NASDAQ:REGI) shares jumped 38.7% to $60.75 after Chevron Corp (NYSE:CVX) announced an agreement to acquire the company. IntriCon Corporation (NASDAQ:IIN) gained 37.3% to $23.91 after the company agreed to be acquired by an affiliate of Altaris Capital Partners for $241 million. IntriCon also posted Q4 EPS of $0.23. NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) climbed 30.5% to $2.01 after gaining around 8% on Friday. First Horizon Corporation (NYSE:FHN) shares climbed 30.4% to $23.80 after TD announced a
U.S. stocks pared some of its losses with the Nasdaq turning positive midway through trading on Monday, amid the ongoing Russia-Ukraine conflict, which has led to increased US sanctions on Russia. The Dow traded down 0.41% to 33,920.57 while the NASDAQ rose 0.73% to 13,794.09. The S&P also fell, dropping, 0.02% to 4,383.71. Check out this: Insiders Buy Around $98M Of 3 Stocks Leading and Lagging Sectors Energy shares climbed by 2% on Friday. Meanwhile, top gainers in the sector included Renewable Energy Group, Inc. (NASDAQ:REGI), up 39% and Nordic American Tankers Limited (NYSE:NAT) up 23%. In trading on Friday, consumer staples shares fell by 1.2%. Top Headline Dentsply Sirona
U.S. stocks opened on a downbeat note this morning, amid the ongoing Russia-Ukraine conflict, which has led to increased US sanctions on Russia. Following the market opening Monday, the Dow traded down 1.38% to 33,587.55 while the NASDAQ fell 0.61% to 13,611.57. The S&P also fell, dropping, 1.12% to 4,335.65. Check out this: Insiders Buy Around $98M Of 3 Stocks Leading and Lagging Sectors Energy shares climbed by 0.8% on Friday. Meanwhile, top gainers in the sector included Renewable Energy Group, Inc. (NASDAQ:REGI), up 38% and Nordic American Tankers Limited (NYSE:NAT) up 21%. In trading on Friday, financials shares fell by 2.1%. Top Headline Dentsply Sirona Inc (NASDAQ:XRAY)